BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving...
...disease that has seen only one targeted therapy approved in the past 50 years. For Alpine...
...upadacitinib and BTK inhibitor ABBV-105 in a Phase II systemic lupus erythematosus (SLE) trial, the Alpine...
BioCentury | Dec 17, 2019
Clinical News

BeiGene looks beyond Phase III setback to build case for Brukinsa

...into the market for several indications, including going head-to-head with Imbruvica in the Phase III ALPINE...
BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

...at Forma Therapeutics Inc.; Carruthers was interim president and CFO at Nivalis Therapeutics Inc. (now Alpine...
BioCentury | Jul 15, 2019
Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

...have disclosed compounds against ENPP1 for cancer, according to BioCentury’s BCIQ database. Mitchell Gold of Alpine...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...The effect is to turn PD-1 into a activator rather than repressor ( 7557 ). Alpine...
...and Institutions Mentioned Alligator Bioscience AB (NASDAQ:OMX; SSE:ATORX), Lund, Sweden Alphamab Oncology Ltd., Suzhou, China Alpine...
...3 VEGF - Vascular endothelial growth factor Allison Johnson, Staff Writer AMG 119 JNJ-61186372, JNJ-6372 KN046 tebentafusp (IMCgp100, ImmTAC-gp100) Alligator Bioscience AB Alpine...
BioCentury | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

...Kite ends immunotherapy deal with Alpine Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated...
...deal granted the Gilead Sciences Inc. (NASDAQ:GILD) unit an exclusive license to two programs from Alpine's...
...Compound #), INC424 (Compound #), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) lanifibranor (iva337) NovoTTF-100L, Tumor Treating Fields (TTFields) Alpine...
BioCentury | May 15, 2019
Company News

May 15 Company Quick Takes: Approvals for Bavencio in RCC, Venclexta-Gazyva combo; plus Adaptimmune, Alpine, Advaxis

...T cells Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) partnered to develop Alpine's...
...to license global rights to develop and commercialize SPEAR T cells incorporating the resulting proteins. Alpine...
...1 Mark Zipkin, Staff Writer Axalimogene filolisbac (ADXS11-001, adxs-hpv, lovaxin c) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Adaptimmune Therapeutics plc Advaxis Inc. Alpine...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Souped-up CARs at ASH 2018

...centers on the checkpoint protein PD-1, whose natural role is to inhibit T cells. 3) Alpine...
...receptor-ligand interactions increase homing of the CAR NK cells to lymphomas. Companies and Institutions Mentioned Alpine...
...CD274) - Programmed cell death 1 ligand 1 TCR - T cell receptor Allison Johnson, Staff Writer Alpine...
BioCentury | Dec 1, 2017
Financial News

Mavupharma raises 20M in series A round for STING modulators

...Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine...
BioCentury | Nov 29, 2017
Financial News

Mavupharma raises $20M series A for STING

...Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine...
Items per page:
1 - 10 of 43